Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2…
Sector
Healthcare
Exchange
NASDAQ
Country
US
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Relmada Therapeutics (RLMD) Analysis Tools & Insights
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.